Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study

Cancer

Volumn 83, Issue 10, 1998, Pages 2099-2104

  Astoul, Philippe ^a   Picat Joossen, Diane ^a   Viallat, Jean Regis ^b   Boutin, Christian ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Immunotherapy; Interleukin 2; Intracavitary treatment; Malignant pleural mesothelioma; Pleura; Thoracoscopy

Indexed keywords

AMINOTRANSFERASE; CREATININE; RECOMBINANT INTERLEUKIN 2; RU 49697; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC BIOPSY; FEVER; HUMAN; INTRAPLEURAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORACOSCOPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE; THORACOSCOPY; TREATMENT OUTCOME;

EID: 0032533285     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3     Document Type: Article

References (24)

1. Rush VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:1-9.
2. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
3. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of 5-year experience, with special reference radiotherapy. Am J Clin Oncol 1990; 13:4-9.
4. Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, et al. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987;47:2184-7.
5. Hinuma S, Narvo K, Shiho O, Tsukamoto K. Characteristics of murine nonspecific killer cells induced in vivo by recombinant human interleukin-2. Immunology 1986;59: 251-9.
6. Robinson BWS, Manning LS, Bowman RV, Christmas TI, Musk AW, Davis MR, et al. The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 1993;3:195-8.
7. Manning LS, Bowman RV, Darby SB, Robinson BWS. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis 1989;139:1369-74.
8. Astoul Ph, Viallat IR, Laurent JC, Brandely M, Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103:209-13.
9. Viallat JR, Boutin C, Rey F, Astoul Ph, Farisse P, Brandely M, et al. Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer 1993; 71:4067-71.
10. Astoul Ph, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer 1994;73:308-13.
11. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 1976;31: 15-24.
12. Boutin C, Rey F, Gouvernet I, Viallat JR, Astoul Ph, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer 1993;73: 394-404.
13. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedure in patients with pleural mesothelioma: a randomized trial of radiotherapy. Chest 1995;108:754-8.
14. Driesen P, Boutin C, Viallat JR, Astoul Ph, Vialette JP, Pasquier J. Implantable access system for prolonged intrapleural immunotherapy. Eur Respir J 1994;7: 1989-92.
15. World Health Organization. Handbook for reporting results of cancer treatment. WHO offset publication 48. Geneva: WHO, 1979.
16. Kaplan GL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
17. West WH, Tauer KW, Vanelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion rIL-2 in adoptive immunotherapy in advanced cancer. N Engl J Med 1987;316: 898-905.
18. Goey SH, Eggerrmont AMM, Punt CJA, Slingerland R, Gratama JW, Oosterom R, et al. Intrapleural administration of interleukin-2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995;72:1283-8.
19. Siegel JP, Puri RJ. Interleukin-2 toxicity. J Clin Oncol 1991; 9:694-704.
20. Klempner MS, Noring R, Mier JW, Atkin MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-65.
21. Jablons D, Bolton E, Mertins S, Rubin M, Pizzo P, Rosenberg SA, et al. IL-2 based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J Immunol 1990;144:3630-6.
22. Richards JM, Gilewski TA, Vogelzang NJ. Association of interleukin-2 therapy with staphylococcal bacteremia. Cancer 1991;67:1570-5.
23. Phillips JH, Lanier LL. Dissection of the lymphokine-actived killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164:814-25.
24. Astoul Ph, Nussbaum E, Boutin C. Natural killer cell-mediated cytotoxicity of blood lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2. Int J Oncol 1995;6:431-6.